Anti-CD70 and BCR-ABL inhibitor combination therapy
US11571475B1 · kind B1 · utility
1Cited by
31References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 9, 2019 |
| Grant date | Feb 7, 2023 |
| Priority date | — |
| Expiry date | May 9, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods and compositions for the treatment of a BCR-ABL1 related disorder (e.g., chronic myelogenous leukemia) using a therapeutic combination of a WNT signaling pathway inhibitor and a BCR-ABL1 tyrosine kinase inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.